stock trading education


Amazon.com’s (NSDQ:AMZN)double digit growth story continues to stay in trend despite the companys top line increasing in the tens of billions each year. Amazons annual revenue has grown around the 20% level in the last three years, and during the first nine months of fiscal 2016, Amazons total revenue has shot up from $71.259 billion last year to $92.246 billion this year, a growth of 29.45%. Top line growth has indeed accelerated despite the fact that the retailer’s quarterly revenues are coming in at above the $30 billion mark.


To grow at above 20% when your sales are more than $30 billion per quarter is no mean achievement, and to do that when you are operating in a highly competitive environment is even more difficult. (See also:Does Amazon.com (AMZN) Have Enough Fuel To Drive The Stock Above $1000 A Share?)

stock trading education: Zion Oil & Gas Inc(ZN)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 0.76 percent. Meanwhile, top losers in the sector included Whiting Petroleum Corp (NYSE: WLL), down 6 percent, and Zion Oil & Gas, Inc. (NASDAQ: ZN) down 7 percent.

  • [By Lisa Levin]

    Shares of Zion Oil & Gas, Inc. (NASDAQ: ZN) got a boost, shooting up 20 percent to $5.07.

    Spark Energy Inc (NASDAQ: SPKE) shares were also up, gaining 12 percent to $19.40. Guggenheim upgraded Spark Energy from Neutral to Buy.

  • [By Lisa Levin]

    Shares of Zion Oil & Gas, Inc. (NASDAQ: ZN) got a boost, shooting up 47 percent to $6.21.

    Spark Energy Inc (NASDAQ: SPKE) shares were also up, gaining 10 percent to $19.10. Guggenheim upgraded Spark Energy from Neutral to Buy.

stock trading education: Edwards Lifesciences Corporation(EW)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achieva ble expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.


    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan. Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat. Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share. Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.


    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.


    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

stock trading education: Lions Gate Entertainment Corporation(LGF)

Advisors’ Opinion:

  • [By Monica Gerson]

    Lions Gate Entertainment Corp. (USA) (NYSE: LGF) is projected to post a quarterly loss at $0.01 per share on revenue of $740.67 million.


    Eaton Vance Corp (NYSE: EV) is estimated to report its quarterly earnings at $0.48 per share on revenue of $321.42 million.

  • [By Ben Levisohn]

    Starz (STRZA) has jumped 14% to$32.16 after agreeing to be purchased by Lions Gate Entertainment (LGF) in a deal that values Starz at about $4.4 billion. Lions Gate has climbed 9.4% to $22.90.

  • [By Ben Levisohn]

    Here we think names trading in the mid-single digit multiple range such as AMC Networks (AMCX) should benefit the most as should Lions Gate Entertainment (LGF) / Starz (STRZA), Viacom (VIAB), Viacom (VIA) and Scripps Networks Interactive (SNI).

stock trading education: American Express Company(AXP)


Advisors’ Opinion:

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded down 1.28% at $79.31. The stock’s 52-week range is $57.15 to $82.00. Volume was just above the daily average of around 4 million shares. The credit card issuer had no specific news.

  • [By Cooper Creagan]

    Since then, the money spent using prepaid cards has nearly doubled, as big players like Wal-Mart Stores Inc. (NYSE: WMT) and American Express Co. (NYSE: AXP) have entered the game with the prepaid Bluebird card.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded up 1.27% at $76.82. The stock’s 52-week range is $50.27 to $78.00, and the high was posted this afternoon. Volume was about 70% higher than the daily average of around 3.6 million shares. The company’s shares were upgraded to Buy at BofA/Merrill Lynch.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded up 2.35% at $81.94. The stock’s 52-week range is $56.57 to $82.00, a new high posted this afternoon. Volume was about 20% below the daily average of around 22.2 million shares. The company had no specific news.

  • [By Virendra Singh Chauhan]

    Banking, as a whole, is another sector which will benefit from a higher interest rate scenario. It is here that Berkshire will benefit from its large investments in publicly listed financial institutions. As of Sept 30, 2016, Berkshire’s investments in public financial institutions, at $42 Billion, accounted for 33% of the total holdings in public listed companies. The stocks of most large financial institutions have rallied since the election results were declared. Wells Fargo (NYSE:WFC), one of Berkshire’s largest holding is up nearly 26% since the election results were declared while American Express (NYSE:AXP), the second largest financial holding in the Berkshire portfolio is up nearly 12% in the similar time frame.

stock trading education: Kinross Gold Corporation(KGC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Kinross Gold Corporation (USA) (NYSE: KGC) is projected to post a quarterly loss at $0.01 per share on revenue of $808.09 million.

    Crocs, Inc. (NASDAQ: CROX) is expected to report its quarterly earnings at $0.05 per share on revenue of $265.90 million.

  • [By Lisa Levin]

    Friday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Kinross Gold Corporation (USA) (NYSE: KGC) and Yamana Gold Inc. (USA) (NYSE: AUY).

  • [By Lee Jackson]

    Kinross Gold Corp. (NYSE: KGC) may be the stock that give investors the most amount of leverage on a gold rebound. Management reduced the company’s annual capital expenditures forecast to $1.45 billion from $1.6 billion, saving $180 million from its cost restructuring initiatives. Cancellation of its upcoming semiannual dividend payment to its shareholders will save $182 million per year. Kinross expects to produce gold at a cost of $1,000 to $1,200 an ounce this year. The Merrill Lynch target is $7.00, and the consensus target is $6.55. The dividend, which soon will be cancelled, has a yield of 2.9%.

Leave a Reply

Your email address will not be published. Required fields are marked *